SPRUCE BIOSCIENCES, INC.
No enriched coverage for $SPRB in the last 7 days.
No SEC Form 4 filings for $SPRB in the last 30 days.
See all $SPRB insider activity →Analysts from H.C. Wainwright and Deutsche Bank maintained Buy ratings on Spruce Biosciences (SPRB), PDS Biotechnology (PDSB), and BioNTech SE (BNTX). Price targets set at $150, $7, and $140 respectively. Current share prices are $63.40, $0.22, and $114.05. Analyst consensus for SPR and BNTX is Strong Buy, with upsides of 160.4% and 12.9% respectively.
Spruce Biosciences (SPRB) stock rose 4.1% in pre-market trading to $64 after H.C. Wainwright reiterated a Buy rating and $150 price target, citing positive FDA feedback on its TA-ERT therapy for Sanfilippo Syndrome Type B. The FDA endorsed the company's analytical strategies, supporting a planned BLA submission in Q4 2026. Analysts maintain a Strong Buy consensus with targets ranging from $104 to $230. The broader market's risk-on tone also contributed to the gain.
SPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential
Recent SPRB coverage spans financial news, market movers and earnings.
Potential upside of ~140% from current price.
Analyst upgrade and positive regulatory feedback lift Spruce Biosciences shares.
Near-term catalysts center on TA-ERT regulatory path (BLA submission and confirmatory study start) plus cash runway updates.
Board and CMO leadership change can affect clinical/medical strategy execution, but the filing provides no new clinical or financial metrics.
The initiation frames a valuation asymmetry around Priority Review Voucher economics, which can attract value-oriented trading interest.
alphai scores every news story that mentions SPRB with an AI model for sentiment and relevance, and aggregates insider trades from SPRUCE BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts from H.C. Wainwright and Deutsche Bank maintained Buy ratings on Spruce Biosciences (SPRB), PDS Biotechnology (PDSB), and BioNTech SE (BNTX). Price targets set at $150, $7, and $140 respectively. Current share prices are $63.40, $0.22, and $114.05. Analyst consensus for SPR and BNTX is Strong Buy, with upsides of 160.4% and 12.9% respectively.
2 min readSpruce Biosciences (SPRB) stock rose 4.1% in pre-market trading to $64 after H.C. Wainwright reiterated a Buy rating and $150 price target, citing positive FDA feedback on its TA-ERT therapy for Sanfilippo Syndrome Type B. The FDA endorsed the company's analytical strategies, supporting a planned BLA submission in Q4 2026. Analysts maintain a Strong Buy consensus with targets ranging from $104 to $230. The broader market's risk-on tone also contributed to the gain.
2 min readSPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential
6 min readSPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001683553 0001683553 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27,
2 min readWall Street analysts issued multiple rating changes. JPMorgan raised American Express (AXP) to Overweight, PT $400. Truist upgraded Biogen (BIIB) to Buy, PT $235, citing upcoming Phase 2 and Phase 3 readouts. JPMorgan also raised Keysight (KEYS) to Overweight, PT $400. Other actions included upgrades for Humana (HUM) and downgrades for Papa John’s (PZZA) and Best Buy (BBY).
4 min readHC Wainwright cut its price target for Spruce Biosciences (NASDAQ:SPRB) from $200 to $150 and kept a “buy” rating, according to a Monday research note cited by Benzinga. The target implies 192.57% upside versus the prior close. Other analysts cited include Oppenheimer “outperform” and Citizens JMP reducing its target to $150. Spruce reported ($8.94) EPS for the quarter on May 13, missing consensus ($7.93).
4 min readDoes Spruce Biosciences, Inc. (SPRB) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 min readSpruce Biosciences Inc. ( NASDAQ:SPRB ) jumped to $175.00 during after-hours trading on Monday, up 34.20% or $44.60 from its closing price. Check out the current price of SPRB stock here. During regular trading hours, SPRB soared $121.58, marking a 1,378.46% gain and closing at $130.40, ...
3 min readShares of Spruce Biosciences, Inc. ( NASDAQ:SPRB ) are surging Monday after the biotech company shared an important regulatory update about one of its therapy treatments. What To Know: Spruce Biosciences, which produces novel therapies for neurological disorders, said the U.S.
2 min read
